Alert Price: $0.8866
Company Website | Recent News
Earlier we told you that we came across a fantastic trade opportunity that has the potential to double in price.
So without further ado, we ask that you turn your immediate attention to EVAHF (EGF Theramed Health Corp.).
This is one of the most attractive opportunities we've seen in quite some time for several reasons.
Is Listed On Major Exchanges In Three Different Countries (U.S., Canada, and Germany)
Trades On The OTCQB, Which Means That It Is Current In Its Reporting, Undergoes Annual Verification & Certification, And Is Not In Bankruptcy
Has A Razor Thin Float Of Just 2.9M
Recently Completed A Big-Time Acquisition
Is Now Operating In A Mental Health Market That Many Experts Believe Is Going To Explode Due To The Covid-19 Epidemic
EVAHF is cut from the same cloth as our past mega-winners.
The Company recently closed a joint venture transaction with Pharmadelic Labs Corp. in which they acquired a 30% interest in the Biosynthesis company.
With this recent acquisition EVAHF is now on the cutting edge when it comes to the treatment of mental health.
EVAHF has begun to research psilocybin and psychedelic extraction and processing for its Las Vegas extraction lab. Psilocybin microdosing is known to reduce stress, anxiety and pain without many of the side effects associated with traditional pharmacology products that have been prescribed for the same issues.
This comes at a time when a research study suggests that as many as 150,000 additional people could die from mental health-related outcomes of COVID-19
We are anticipating a big move from EVAHF, as this acquisition news starts to grab the attention of the Street.
This could easily be our next trade idea to double in price, so we suggest you start your research now, and add EVAHF to the top of your watchlist immediately.
About EGF Theramed Health Corp. (OTCQB:EVAHF CSE:MED FWB:AUHP)
EGF Theramed Health Corp. is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is seeking to be the first company to offer a complete quality assured vertically integrated "Natural Products and Herbal Health System" for monitoring, dosing, and recording the effects of natural products on the cardiovascular system.
Through the Company’s recent acquisition of a 30% equity interest in Pharmadelic Labs Corp. it has begun to research psilocybin and psychedelic extraction and processing for its Las Vegas extraction lab. Psilocybin microdosing is known to reduce stress, anxiety and pain without many of the side effects associated with traditional pharmacology products that have been prescribed for the same issues.
About Pharmadelic Labs Corp.
Pharmadelic Labs is genetically designing proprietary processes to help create pharmaceutical grade psilocybin-derived ingredients in a synthetic lab environment. Genetic engineering and biosynthesis expedite a process that creates unique modified psilocybin ingredients in a far more efficient and cost effective manner than a traditional greenhouse environment.
Pharmadelic Labs aims to develop a portfolio of intellectual property around biosynthesis pathways for creating compounds. This has great potential for application in the pharmaceuticals industry.
The company's patent portfolio will develop as follows:
File for provisional patent applications
Continue to update patents as technology develops
Strengthen existing patents with further applications around biosynthesis pathways as results are known
Further information can be found at http://www.pharmadeliclabs.com
EVAHF Is Now In A Position To Help Solve A $280 Billion Per Year Problem In The U.S.
Mental health is one of the biggest unsolved health problems in the world. It is pervasive; it is estimated that up to one quarter of Americans can suffer a mental disorder in any given year. This has a striking economic impact ; treating mental health is estimated to cost the US more than $280 billion per year - before economic losses due to time off work is calculated. The global antidepressants market is estimated to grow to over $22 billion by 2025 - this represents a huge potential market for psychedelic drugs to enter.
Current treatments such as opioids have potentially harmful side effects such as addictiveness, but psychedelic drugs like psilocybin may avoid these downsides of addiction. An article published by Johns Hopkins University in 2018 recommended that the government downgrade psilocybin's classification to Schedule IV: a drug with "low potential for abuse and low risk of dependence". It has shown promising results in treating depression, as well as in palliative care.
As the government and more pharmaceutical companies recognize the medical treatment potential of psychedelic substances, it is important that access to compounds like psilocybin is made easier. Pharmadelic Labs is aiming to achieve this by creating biosynthesis pathways for psilocybin.
FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression
The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder ( MDD ).
For the second time in a year, the U.S. Food and Drug Administration (FDA) has designated psilocybin therapy — currently being tested in clinical trials — as "breakthrough therapy," an action that is meant to accelerate the typically sluggish process of drug development and review. It is typically requested by a drug company and granted only when preliminary evidence suggests the drug may be an enormous improvement over already available therapy, according to the FDA.
Last year, the FDA granted "breakthrough therapy" status to psilocybin therapy in the still-ongoing clinical trials run by the company Compass Pathways, which are looking into psilocybin's potential to treat severe treatment-resistant depression, or depression in patients who have not improved after undergoing two different antidepressant treatments, according to New Atlas.
Coronavirus Pandemic Could Push Suicide, Drug Deaths as High as 150K, Study Says
There is a research model going around that suggests as many as 150,000 additional people could die from mental health-related outcomes of COVID-19
The federal mental health czar is calling for more money to expand services to help people suffering amid the social isolation imposed by the coronavirus pandemic, as a new study estimates related deaths from alcohol, drug overdose and suicide could reach 150,000.
"We see very troubling signs across the nation," said Dr . Elinore McCance-Katz, assistant secretary at Department of Health and Human Services and head of the Substance Abuse and Mental Health Administration. "There's more substance abuse, more overdoses, more domestic violence and neglect and abuse of children."
McCance-Katz said the agency wants more money for services to address an anticipated surge in need for mental health and addiction treatment, which was already in short supply. She cited HHS' own substance abuse and mental health research and a February report in the British journal The Lancet on the psychological effects of quarantine
The Lancet study said the effects can include post-traumatic stress disorder and suicide and are "wide-ranging, substantial, and can be long lasting." That's especially true if there isn't a clear end in sight, like now, said McCance-Katz.
"The impetus is COVID-19, but the need was there before and it's just been increased by what's happened as a result of the virus," she said.
The new study, released Friday by the Well Being Trust and the American Academy of Family Physicians, factored in isolation and uncertainty when it calculated the expected deaths from suicide, alcohol and drugs, based on nine unemployment scenarios.
The likely toll from these "deaths of despair" was the loss of an additional 75,000 lives, the study found. Death estimates ranged from 27,644 if the economy recovers quickly, to 154,037 if recovery is slow.
Based on the data we've read, it appears that a sharp increase in spending toward mental health is inevitable.
This is certainly not the most uplifting news, but we do see it as a catalyst for EVAHF.
EVAHF Has A Razor Thin Float And Tremendous Upside Potential
We did our very own , and see the potential for a major move from here.
Break From . Reversal Signal
Reclaimed 50 Day Moving Average As Support
Crossed Above Zero-Line
Momentum Cross Above Zero Line In Advance Of Price Rise.
EVAHF closed down over 11 percent today, creating a very attractive 'buy the dip' opportunity.
As we've seen with our past winners, these low-float alerts have the tendency to bounce back hard, and can go viral at any moment.
The Company is trading well below its 52-week high of $18.30, giving it almost unlimited upside potential from today's alert price.
The Bottom Line
With its razor thin float, EVAHF is a day traders dream come true.
The Company appears to be in the midst of a major growth stage, and could rally hard from today's alert price.
We love their recent strategic acquisition, and believe it will serve as a major catalyst in the very near future.